D I G I T A L D I A G N O S T I C S
Two years ago , the global AI in healthcare market was valued at US $ 16.3 billion , with an expectation that it would reach US $ 173.6 billion by 2029 . It ’ s a market that is growing at a remarkable pace thanks to its ability to be used in various parts of the drug discovery process . The power of this technology is something that the pharmaceutical and biomedical industry is already harnessing to discover drugs with greater speed and reduced costs .
We can also expect strong advances in 2025 in AI ’ s ability to discover cancer drugs with greater precision than ever seen before and this can lead to improving outcomes for investors , practitioners and most importantly for patients .
How is AI accelerating drug discovery ?
AI-driven drug discovery is evolving rapidly , encompassing the many stages throughout the entire drug development process from the very beginning of designing a novel therapeutic to its eventual approval for patient use .
Our expertise at Oxford Drug Design lies in the earliest stages of this process . This is when a specific molecule – a chemical compound with the potential to become a therapeutic drug – is designed , discovered and developed before it reaches a clinical setting .
The computational capability of our platform , Synth AI , is a powerful multitool approach to designing novel drugs with remarkable accuracy . This pioneering , validated technology is completely disease-agnostic , meaning it can be applied across any therapeutic area .
In this article , Dr Alan D Roth , CEO of Oxford Drug Design , explains how AI is transforming future medical treatments for major diseases and illnesses such as cancer and cystic fibrosis , how and why we will see advances in Machine Learning grow this year , and how better treatments for these diseases and illnesses are closer than we think .
We ’ ve already demonstrated its versatility in our own pipeline , particularly in oncology and infectious diseases . However , this capability has been proven in the drug discovery programs of other pharmaceutical and biotech companies across numerous other diseases thus demonstrating its broad applicability . Another key advantage of a highly versatile AI drug discovery platforms such as ours is that it can be used to find new molecules against a wide variety of targets .
Modern drug discovery is largely driven by the selection of such a disease target , the body ’ s biochemicals that malfunction leading to disease . Computational technologies available to the drug discovery industry today can often work for numerous targets , regardless of the disease or the nature of the target itself . Prior to the availability of computational
WHAT ’ S NEXT IN AI DRUG DISCOVERY IN 2025 ?
www . intelligenthealth . tech 63